ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $39 | – | $53 | – |
| Short-Term Investments | $0 | – | $1 | – |
| Receivables | $3 | – | $5 | – |
| Inventory | $1 | – | $0 | – |
| Other Curr. Assets | $0 | – | $3 | – |
| Total Curr. Assets | $43 | – | $62 | – |
| Property Plant & Equip (Net) | $3 | – | $4 | – |
| Goodwill | $0 | – | $0 | – |
| Intangibles | $0 | – | $0 | – |
| Long-Term Investments | $0 | – | $0 | – |
| Tax Assets | $0 | – | $0 | – |
| Other NC Assets | $0 | – | $0 | – |
| Total NC Assets | $3 | – | $4 | – |
| Other Assets | $0 | – | $0 | – |
| Total Assets | $46 | – | $66 | – |
| Liabilities | – | – | – | – |
| Payables | $2 | – | $2 | – |
| Short-Term Debt | $3 | – | $1 | – |
| Tax Payable | $0 | – | $0 | – |
| Deferred Revenue | $0 | – | $0 | – |
| Other Curr. Liab. | $7 | – | $24 | – |
| Total Curr. Liab. | $12 | – | $28 | – |
| LT Debt | $10 | – | $3 | – |
| Deferred Rev, NC | $0 | – | $0 | – |
| Deferred Tax Liab, NC | $0 | – | $0 | – |
| Other NC Liab. | $0 | – | $13 | – |
| Total NC Liab. | $11 | – | $16 | – |
| Other Liabilities | $0 | – | $0 | – |
| Cap. Leases | $0 | – | $0 | – |
| Total Liabilities | $22 | – | $44 | – |
| Equity | – | – | – | – |
| Pref Stock | $0 | – | $0 | – |
| Common Stock | $3 | – | $3 | – |
| Retained Earnings | -$0 | – | -$1 | – |
| AOCI | -$28 | – | -$29 | – |
| Other Equity | $49 | – | $49 | – |
| Total Equity | $23 | – | $22 | – |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | – | $0 | – |
| Total Liab. & Tot. Equity | $46 | – | $66 | – |
| Net Debt | -$25 | $0 | -$49 | $0 |